ReviewSeminars in liver disease2021
Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review.
Review in Seminars in liver disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.Scientific reports · 2023Pooled it
- Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2022Pooled it
- Comparison of liver T1 estimates generated by breath-hold 3D FSPGR and free-breathing 3D radial stack-of-stars FSPGR variable flip angle T1 mapping sequences.European journal of radiology open · 2026Article
- Impact of multidisciplinary steatotic liver disease management on bariatric surgery referral and clinical outcomes: A retrospective cohort study.World journal of hepatology · 2026Article
- Nicotinamide riboside enhances liver regeneration via the MCART1/ASB3 axis in obesity-compromised rats.Hepatology communications · 2026Article
- Impact of Pathological Grades of Metabolic Dysfunction-Associated Steatotic Liver Disease on Weight Loss Following Laparoscopic Sleeve Gastrectomy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Risk of colorectal cancer after weight loss in the obese: a pooled cohort study.Annals of gastroenterology · 2025Article
- Unveiling functionality and conducting two-sample mendelian randomization on WGCNA-identified oxidative stress-related hub genes in metabolic dysfunction-associated fatty liver disease.Biochemistry and biophysics reports · 2024Article
- Impairment in Right Ventricular-Pulmonary Arterial Coupling in Overweight and Obesity.Journal of clinical medicine · 2024Article
- Matcha alleviates obesity by modulating gut microbiota and its metabolites.Current research in food science · 2024Article
- Diagnostic Performance of 2D Shear Wave (2D-SWE) for Liver Fibrosis in Adults Undergoing Bariatric Surgery.Obesity surgery · 2023Article
- Weight Loss Improves Liver Dysfunction and Dipstick Proteinuria in Obesity: The Japan Specific Health Checkups Study.JMA journal · 2023Article
- Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Article
- The Impact of Bariatric-Surgery-Induced Weight Loss on Patients Undergoing Liver Transplant: A Focus on Metabolism, Pathophysiological Changes, and Outcome in Obese Patients Suffering NAFLD-Related Cirrhosis.Journal of clinical medicine · 2022Review
- Physiopathology of nonalcoholic fatty liver disease: from diet to nutrigenomics.Current opinion in clinical nutrition and metabolic care · 2022Review
- G Protein-Coupled Receptor GPR35 Suppresses Lipid Accumulation in Hepatocytes.ACS pharmacology & translational science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
With the recent urbanization and globalization, the adult obesity rate has been increasing, which was paralleled with a dramatic surge in the incidence and prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD poses a growing threat to human health as it represents the most common cause of chronic liver disease in developed countries. It encompasses a wide spectrum of conditions starting from a build-up of fat in hepatocytes (steatosis), to developing inflammation (steatohepatitis), and reaching up to cirrhosis. It is also associated with higher rates of cardiovascular mortalities. Therefore, proper timely treatment is essential and weight loss remains the cornerstone in the treatment of obesity-related liver diseases. When diet, exercise, and lifestyle changes are not successful, the current recommendation for weight loss includes antiobesity medications and bariatric endoscopic and surgical interventions. These interventions have shown to result in significant weight loss and improve liver steatosis and fibrosis. In the current literature review, we highlight the expected outcomes and side effects of the currently existing options to have a weight-centric NAFLD approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.